ASTRAZEN - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 2.8
| Stock Code | ASTRAZEN | Market Cap | 21,126 Cr. | Current Price | 8,436 ₹ | High / Low | 9,850 ₹ |
| Stock P/E | 110 | Book Value | 349 ₹ | Dividend Yield | 0.38 % | ROCE | 29.3 % |
| ROE | 23.3 % | Face Value | 2.00 ₹ | DMA 50 | 8,482 ₹ | DMA 200 | 8,550 ₹ |
| Chg in FII Hold | 0.07 % | Chg in DII Hold | 0.24 % | PAT Qtr | 45.7 Cr. | PAT Prev Qtr | 31.6 Cr. |
| RSI | 48.2 | MACD | -17.9 | Volume | 7,459 | Avg Vol 1Wk | 4,747 |
| Low price | 7,552 ₹ | High price | 9,850 ₹ | PEG Ratio | 7.42 | Debt to equity | 0.13 |
| 52w Index | 38.5 % | Qtr Profit Var | -26.6 % | EPS | 75.0 ₹ | Industry PE | 32.5 |
ASTRAZEN shows mixed signals for swing trading. The valuation is stretched with a P/E of 110 compared to the industry average of 32.5, and the PEG ratio of 7.42 indicates growth is not justifying the price. Technical indicators are neutral to bearish: RSI at 48.2 (neutral zone) and MACD at -17.9 (bearish). The stock is trading close to its 50 DMA (8,482 ₹) and 200 DMA (8,550 ₹), suggesting indecision. Volume is slightly above average, showing moderate interest. While fundamentals like ROCE (29.3%) and ROE (23.3%) are strong, short-term swing potential looks limited.
🔑 Optimal Entry Price: 8,200–8,300 ₹ (near support, below DMA levels).
📤 Exit Strategy if Holding: Consider exiting near 8,900–9,000 ₹ resistance unless momentum improves.
✅ Positive
- 📈 Strong ROCE and ROE reflect efficient capital use.
- 💰 Low debt-to-equity ratio (0.13) ensures financial stability.
- 📊 Institutional investors (FII/DII) increased holdings slightly, showing confidence.
- 📉 Dividend yield, though small, provides shareholder value.
⚠️ Limitation
- 📉 Very high P/E ratio compared to industry peers.
- 📊 PEG ratio (7.42) suggests poor valuation relative to growth.
- 📉 Quarterly profit variation (-26.6%) raises concerns about earnings consistency.
- 📉 RSI and MACD show weak momentum, limiting upside potential.
📰 Company Negative News
- 📉 Decline in quarterly profit variation (-26.6%).
- ⚠️ Overvaluation risk due to stretched multiples.
🌟 Company Positive News
- 📈 PAT improved sequentially (45.7 Cr vs 31.6 Cr).
- 📊 Strong efficiency metrics (ROCE, ROE).
- 📉 Stable debt profile supports resilience.
🏭 Industry
- 📊 Industry P/E at 32.5, much lower than ASTRAZEN, showing sector is moderately valued.
- 📈 Pharma sector benefits from defensive demand.
- ⚠️ Valuation gap may limit upside compared to peers.
📌 Conclusion
ASTRAZEN is not an ideal swing trade candidate due to overvaluation and weak technical momentum. Entry is best near 8,200–8,300 ₹ with cautious exit around 8,900–9,000 ₹. Long-term fundamentals remain strong, but short-term swing potential is limited.